Newcastle Disease Virus/HK84: Next Potential Star for Targeted Immunotherapy of Hepatocellular Carcinoma?

Affiliations

¹ Department of Pharmacology, Shantou University Medical College, Shantou, Guangdong, China.
² Department of Navy Environmental and Occupational Health, Naval Medical University, Shanghai, China.

Editorial

Weiyi Huang et al. J Clin Transl Hepatol. 2022.

. 2022 Apr 28;10(2):179-180.

doi: 10.14218/JCTH.2021.00553. Epub 2022 Mar 2.

¹ Department of Pharmacology, Shantou University Medical College, Shantou, Guangdong, China.
² Department of Navy Environmental and Occupational Health, Naval Medical University, Shanghai, China.

No abstract available

Conflict of interest statement

The authors have no conflict of interests related to this publication.

1. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi: 10.1038/s41572-020-00240-3. - DOI - PubMed
1. Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450–1462. doi: 10.1056/NEJMra1713263. - DOI - PubMed
1. Chen L, Niu Y, Sun J, Lin H, Liang G, Xiao M, et al. Oncolytic Activity of Wild-type Newcastle Disease Virus HK84 Against Hepatocellular Carcinoma Associated with Activation of Type I Interferon Signaling. J Clin Transl Hepatol. 2021 doi: 10.14218/JCTH.2021.00284. - DOI - PMC - PubMed
1. Davola ME, Mossman KL. Oncolytic viruses: how “lytic” must they be for therapeutic efficacy? Oncoimmunology. 2019;8(6):e1581528. doi: 10.1080/2162402X.2019.1596006. - DOI - PMC - PubMed
1. Kole C, Charalampakis N, Tsakatikas S, Vailas M, Moris D, Gkotsis E, et al. Immunotherapy for Hepatocellular Carcinoma: A 2021 Update. Cancers (Basel) 2020;12(10):2859. doi: 10.3390/cancers12102859. - DOI - PMC - PubMed